A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Single‐Dose and Multiple‐Rising‐Dose Study of the BTK Inhibitor TAK‐020 in Healthy Subjects

A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Single‐Dose and Multiple‐Rising‐Dose Study of the BTK Inhibitor TAK‐020 in Healthy Subjects

Bruton’s tyrosine kinase (BTK) is a target for treatment of hematologic malignancies and autoimmune diseases. TAK‐020 is a highly selective covalent BTK inhibitor that inhibits both B cell receptor and fragment crystallizable receptor signaling. We assessed the safety/tolerability and pharmacokineti...

Full description

Bibliographic Details
Main Authors: Ehsanollah Esfandiari, Mary Chen, Glennda Smithson, Derek Blair, Helene Faessel, John Wagner, Lachy Mclean, Eric R. Fedyk
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.12871

Internet

https://doi.org/10.1111/cts.12871

Similar Items